Mandatory Joint Clinical Assessments For EU HTAs May Be ‘Counterproductive’
Executive Summary
The mandatory joint clinical assessments that the European Commission recently proposed for EU member states will be counterproductive if the highest standards of evaluation are not met, warns Health Action International.
You may also be interested in...
Industry Welcomes Mandatory EU Joint Clinical Assessments For HTA
Draft proposals to improve EU-wide cooperation on health technology assessments, including mandatory joint clinical assessments, have won support from EFPIA, the European Federation of Pharmaceutical Industries and Associations.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.